BAM
PTCT icon

Blueshift Asset Management’s PTC Therapeutics PTCT Stock Holding History

Blueshift Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,521
Closed -$225K – 394
2023
Q2 		$225K Buy
+5,521
New +$270K 0.09% 278
2022
Q1 		– Sell
-5,046
Closed -$201K – 1079
2021
Q4 		$201K Buy
+5,046
New +$193K 0.02% 759
2021
Q2 		– Sell
-8,468
Closed -$401K – 1122
2021
Q1 		$401K Buy
8,468
+828
+11% +$49.2K 0.04% 547
2020
Q4 		$466K Buy
+7,640
New +$450K 0.06% 426
2019
Q4 		– Sell
-6,777
Closed -$229K – 990
2019
Q3 		$229K Buy
+6,777
New +$295K 0.03% 606

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Blueshift Asset Management's PTCT Position: Q3 2023 in Review

Blueshift Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 5,521 shares — an estimated $225K sold.

Blueshift Asset Management first reported a position in PTCT in Q3 2019 and held it in 5 quarters. The position peaked at $466K in Q4 2020. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Blueshift Asset Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Blueshift Asset Management sold 5,521 PTC Therapeutics shares in Q3 2023, an estimated $225K.
  • Blueshift Asset Management first reported a position in PTC Therapeutics in Q3 2019 and held it in 5 quarters.
  • Blueshift Asset Management's PTC Therapeutics position peaked at $466K in Q4 2020.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Blueshift Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.